Literature DB >> 15270860

CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.

A W Lin1, S A Gonzalez, S Cunningham-Rundles, G Dorante, S Marshall, A Tignor, C Ha, I M Jacobson, A H Talal.   

Abstract

CD3- CD56(+dim) natural killer (NK) cells, which are cytotoxic against virally infected cells, may be important in hepatitis C virus (HCV)-infected patients who are successfully treated with pegylated interferon (PEG-IFN)-alpha. We used flow cytometry to enumerate activated (CD69+) and apoptotic (annexin-V+) dim (CD3- CD56(+dim)) and bright (CD3- CD56(+bright)) NK cells obtained from HCV-infected patients before treatment (n=16) and healthy controls (n=15) in the absence and presence of pegylated interferon (PEG-IFN)-alpha-2b. A subset of HCV-infected patients, subsequently treated with PEG-IFN-alpha-2b in vivo, was determined to have a sustained virological response (SVR, n=6) or to not respond (NR) to treatment (n=5). In the absence of IFN, activated dim (CD3- CD56(+dim) CD69+) NK cells were significantly decreased (P=0.04) while activated apoptotic dim (CD3- CD56(+dim)CD69+ annexin-V+) NK cells tended to be increased (P=0.07) in SVR patients compared with NR patients. Activated bright (CD3-CD56(+bright)CD69+) and activated apoptotic bright (CD3- CD56(+bright)CD69+ annexin-V+) NK cells were significantly correlated (P=0.02 and P=0.01, respectively) with increasing hepatic inflammation. These findings suggest that in the absence of PEG-IFN, activated dim (CD3- CD56(+dim)CD69+) NK cell turnover may be enhanced in SVR compared with NR patients and that activated bright (CD3- CD56(+bright)CD69+) NK cells may play a role in liver inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270860      PMCID: PMC1809111          DOI: 10.1111/j.1365-2249.2004.02523.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns.

Authors:  D G Doherty; S Norris; L Madrigal-Estebas; G McEntee; O Traynor; J E Hegarty; C O'Farrelly
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

Review 2.  Immunology of the healthy liver: old questions and new insights.

Authors:  W Z Mehal; F Azzaroli; I N Crispe
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

3.  Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire.

Authors:  J J Campbell; S Qin; D Unutmaz; D Soler; K E Murphy; M R Hodge; L Wu; E C Butcher
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

4.  Vital involvement of a natural killer cell activation receptor in resistance to viral infection.

Authors:  M G Brown; A O Dokun; J W Heusel; H R Smith; D L Beckman; E A Blattenberger; C E Dubbelde; L R Stone; A A Scalzo; W M Yokoyama
Journal:  Science       Date:  2001-05-04       Impact factor: 47.728

5.  Liver-infiltrating CD56 positive T lymphocytes in hepatitis C virus infection.

Authors:  K Yonekura; T Ichida; K Sato; S Yamagiwa; M Uchida; S Sugahara; S Ito; T Abo; H Asakura
Journal:  Liver       Date:  2000-10

6.  Effect of HIV-1 infection on lymphocyte proliferation in gut-associated lymphoid tissue.

Authors:  A H Talal; C E Irwin; D T Dieterich; H Yee; L Zhang
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

7.  Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway.

Authors:  A Kaser; B Enrich; O Ludwiczek; W Vogel; H Tilg
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

8.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

9.  Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.

Authors:  M A Cooper; T A Fehniger; S C Turner; K S Chen; B A Ghaheri; T Ghayur; W E Carson; M A Caligiuri
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

10.  Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma.

Authors:  N Kawarabayashi; S Seki; K Hatsuse; T Ohkawa; Y Koike; T Aihara; Y Habu; R Nakagawa; K Ami; H Hiraide; H Mochizuki
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

View more
  11 in total

1.  Activation of natural killer cells by hepatitis C virus particles in vitro.

Authors:  M M S Farag; K Weigand; J Encke; F Momburg
Journal:  Clin Exp Immunol       Date:  2011-06-17       Impact factor: 4.330

2.  Reduction of virus burden-induced splenectomy in patients with liver cirrhosis related to hepatitis C virus infection.

Authors:  Tetsuro Sekiguchi; Takeaki Nagamine; Hitoshi Takagi; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

3.  Activation of natural killer cells during acute infection with hepatitis C virus.

Authors:  Barbara Amadei; Simona Urbani; Angelica Cazaly; Paola Fisicaro; Alessandro Zerbini; Parvin Ahmed; Gabriele Missale; Carlo Ferrari; Salim I Khakoo
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

4.  Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Authors:  Xiaoli Hu; Yanfang Jiang; Xiurong Li; Yanhang Gao; Xiaoli Guo; Xiumei Chi; Hongqing Yan; Junyan Feng; Jin Zhong; Bing Sun; Xue Shao; Weihua Xiao; Yu Pan; Junqi Niu
Journal:  J Interferon Cytokine Res       Date:  2013-12-24       Impact factor: 2.607

Review 5.  Innate immune cell networking in hepatitis C virus infection.

Authors:  Banishree Saha; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

Review 6.  Immune responses during acute and chronic infection with hepatitis C virus.

Authors:  Shigeaki Ishii; Margaret James Koziel
Journal:  Clin Immunol       Date:  2008-06-02       Impact factor: 3.969

7.  Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis.

Authors:  Nidal Muhanna; Sarit Doron; Ori Wald; Amjad Horani; Ahmed Eid; Orit Pappo; Scott L Friedman; Rifaat Safadi
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

8.  Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.

Authors:  Donald D Anthony; Sara J Conry; Kathy Medvik; M R Sandhya Rani; Yngve Falck-Ytter; Ronald E Blanton; Michael M Lederman; Benigno Rodriguez; Alan L Landay; Johan K Sandberg
Journal:  J Infect Dis       Date:  2012-07-10       Impact factor: 7.759

9.  Health effects of a forest environment on natural killer cells in humans: an observational pilot study.

Authors:  Tsung-Ming Tsao; Ming-Jer Tsai; Jing-Shiang Hwang; Wen-Fang Cheng; Chang-Fu Wu; Charles-C K Chou; Ta-Chen Su
Journal:  Oncotarget       Date:  2018-03-27

Review 10.  Molecular mechanisms of hepatic apoptosis.

Authors:  K Wang
Journal:  Cell Death Dis       Date:  2014-01-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.